Dapagliflozin attenuates depressive-like behavior of male rats in the forced swim test

Çam, Muhammet Emin; Hazar‐Yavuz, Ayse Nur; Yildiz, Sila; KELEŞ, Rümeysa; Ertaş, Büşra; Kabasakal, Levent

doi:10.1016/j.euroneuro.2018.11.418

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have highlighted their antioxidant, antiinflammatory, and antiapoptotic mechanisms, regardless of their glycaemic control benefits (Shaikh et al, 2016;Sa-Nguanmoo et al, 2017;El-Sahar et al, 2020;Esterline et al, 2020;Wiciński et al, 2020;Muhammad et al, 2021). Dapaglifozin attenuated depressive-like behaviour of male rats in the forced swim test and was also found to be comparable to imipramine in the treatment of mild-to-moderate depression (Cam et al, 2019). In humans, these drugs improved the quality of life of people with diabetes (maybe due to the weight loss observed in the enrolled patients); however, no change in terms of Pittsburgh Sleep Quality, and Beck Anxiety Inventory scores was found.…”

Section: Discussionmentioning

confidence: 99%

The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase

Battini

Manen²,

Gringeri

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Growing evidence supports a bidirectional association between diabetes and depression; promising but limited and conflicting data from human studies support the intriguing possibility that antidiabetic agents may be used to relieve effectively depressive symptoms in diabetic patients. We investigated the potential antidepressant effects of antidiabetic drugs in a high-scale population data from the two most important pharmacovigilance databases, i.e., the FDA Adverse Event Reporting System (FAERS) and the VigiBase.Material and methods: From the two primary cohorts of patients treated with antidepressants retrieved from FDA Adverse Event Reporting System and VigiBase we identified cases (depressed patients experiencing therapy failure) and non-cases (depressed patients experiencing any other adverse event). We then calculated the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Empirical Bayes Geometric Mean (EBGM), and Empirical Bayes Regression-Adjusted Mean (ERAM) for cases versus non-cases in relation with the concurrent exposure to at least one of the following antidiabetic agent: A10BA Biguanides; A10BB Sulfonylureas; A10BG Thiazolidinediones; A10BH DPP4-inhibitors; A10BJ GLP-1 analogues; A10BK SGLT2 inhibitors (i.e., those agents for which preliminary evidence from literature supports our pharmacological hypothesis).Results: For GLP-1 analogues, all the disproportionality scores showed values <1, i.e., statistically significant, in both analyses [from the FAERS: ROR confidence interval of 0.546 (0.450–0.662); PRR (p-value) of 0.596 (0.000); EBGM (CI) of 0.488 (0.407–0.582); ERAM (CI) of 0.480 (0.398–0.569) and VigiBase: ROR (CI) of 0.717 (0.559–0.921); PRR (p-value) of 0.745 (0.033); EBGM (CI) of 0.586 (0.464–0.733); ERAM of (CI): 0.515 (0.403–0.639)]. Alongside GLP-1 analogues, DPP-4 Inhibitors and Sulfonylureas showed the greatest potential protective effect. With regard to specific antidiabetic agents, liraglutide and gliclazide were associated with a statistically significant decrease in all disproportionality scores, in both analyses.Conclusion: The findings of this study provide encouraging results, albeit preliminary, supporting the need for further clinical research for investigating repurposing of antidiabetic drugs for neuropsychiatric disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase

Battini

Manen²,

Gringeri

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In targeted genes, the PPREs (peroxisome proliferator hormone response elements) are particular DNA areas that interact with PPARs [ 18 , 19 ]. They are connate in the fatty acid-binding protein like PPAR-responsive gene promoters that activate transcription of multiple genes involved in various physiological processes shown in Figure 1 [ 20 , 21 ]. The protein structure of various PPARs is fetched from the protein data bank using three PDB ids such as 2P54 (PPARα), 2A5G (PPA, Rβ,), and 3VI8 (PPARγ), shown in Figure 2 [ 22 , 23 , 24 , 25 , 26 ].…”

Section: Structure Of Pparmentioning

confidence: 99%

Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications

et al. 2022

View full text Add to dashboard Cite

The family of nuclear peroxisome proliferator-activated receptors (PPARα, PPARβ/δ, and PPARγ) is a set of ligand-activated transcription factors that regulate different functions in the body. Whereas activation of PPARα is known to reduce the levels of circulating triglycerides and regulate energy homeostasis, the activation of PPARγ brings about insulin sensitization and increases the metabolism of glucose. On the other hand, PPARβ when activated increases the metabolism of fatty acids. Further, these PPARs have been claimed to be utilized in various metabolic, neurological, and inflammatory diseases, neurodegenerative disorders, fertility or reproduction, pain, and obesity. A series of different heterocyclic scaffolds have been synthesized and evaluated for their ability to act as PPAR agonists. This review is a compilation of efforts on the part of medicinal chemists around the world to find novel compounds that may act as PPAR ligands along with patents in regards to PPAR ligands. The structure–activity relationship, as well as docking studies, have been documented to better understand the mechanistic investigations of various compounds, which will eventually aid in the design and development of new PPAR ligands. From the results of the structural activity relationship through the pharmacological and in silico evaluation the potency of heterocycles as PPAR ligands can be described in terms of their hydrogen bonding, hydrophobic interactions, and other interactions with PPAR.

show abstract

Dapagliflozin attenuates depressive-like behavior of male rats in the forced swim test

Cited by 2 publications

References 5 publications

The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase

The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase

Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications

Contact Info

Product

Resources

About